Filing Flows › Cardiff Oncology (CRDF) › Q1 2026
Cardiff Oncology (CRDF) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 14, 2026
Cardiff Oncology (CRDF) reported revenue of $41K for the first quarter 2026 (Q1 2026), -62% from a year earlier and -83% from the quarter before.
Cardiff Oncology, Q1 2026: revenue $41K (-62% year over year), net loss $12.3M, operating cash flow −$12.3M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $41K | -83% | -62% |
| Operating profit | −$12.8M | — | — |
| Net earnings | −$12.3M | — | — |
| Operating cash flow | −$12.3M | — | — |
What changed
Revenue was $41K in Q1 2026, down 62% year over year and down 83% from the previous quarter.
Operating costs exceeded revenue by $12.8M, an operating margin of -31341.5%. Total costs fell 11% while revenue fell 62%. The fastest-growing cost line was SG&A (+53%). The quarter ended with a net loss of $12.3M, wider than the previous quarter's $7.2M loss.
Operating cash flow was −$12.3M. Non-cash charges added back $87K of depreciation and $1.7M of share-based compensation. Working capital and other items used $1.7M.
Questions
What was Cardiff Oncology's revenue in the first quarter 2026?
Cardiff Oncology (CRDF) reported revenue of $41K for the first quarter 2026 (Q1 2026), -62% from a year earlier and -83% from the quarter before.
Source: Cardiff Oncology 10-Q on SEC EDGAR.